coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Breightmet & Little Lever PCN, Bolton (LAD) · Health Inequalities Profile

    PCN U79938 · NHS Greater Manchester Integrated Care Board · 6 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    37,480

    Registered population

    59.2% aged 18–64

    18.8%

    Aged 65+

    ICB 14.9% · England 17.9%

    21.7%

    Ethnic minority (non-White)

    14.7% Asian · England 9.6%

    52.2%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~18,610

    Core20 residents (est.)

    Resident basis; registered basis ~19,423 · see page 3

    6,198

    Hypertension register

    +5.08% in 3 yrs · England +5.60%

    444

    SMI register

    12.2% of Bolton (LAD)'s

    1,192

    COPD register

    Reviews -7.40% in 3 yrs

    Forecast to 2030

    6,922

    Hypertension patients, 2030

    +724 on today

    76.7%

    QRISK ≥20% on statins, 2030

    +3.19pp over 3 yrs

    4.4%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    22
    Three-year clinical trends trail England.

    Of 25 measures, 22 trail England over 2023 to 2025, led by heart failure reviews (-9.5% vs +8.7%) and asthma reviews (-9.2% vs +4.4%).

    48.5 pp
    Wide inter-practice phone access divergence.

    Phone access spans 48.5 pp from 34.8% at The Alastair Ross Medical Practice to 83.3% at Tonge Fold Health Centre, which may reflect triage.

    69.8%
    High current lipid therapy and respiratory reviews.

    Current QRISK ≥ 20% lipid therapy reaches 69.8% (England 63.6%), alongside 81.5% COPD reviews (England 76.4%) and 70.2% asthma reviews (England 65.7%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Dual-ended age demand pairs 22.0% children with 18.8% older adults across 37,480 patients

    Across member practices, the PCN registers 37,480 patients with dual-ended age demand: 22.0% (8,245) are aged 0-17 against 23.7% in Bolton, 21.8% in the ICB and 19.6% in England, while 18.8% (7,054) are aged 65+ against 14.7% in Bolton, 14.9% in the ICB and 17.9% in England. Resident Census estimates show a 21.7% ethnic minority share, including 14.7% Asian or Asian British residents against 20.1% in Bolton, 13.6% in the ICB and 9.6% in England. This structure may shape paediatric and older-adult service demand. Registered patient counts and resident Census bases differ.

    Age profile

    0–1722.0%
    18–6459.2%
    65+18.8%

    65+: ICB 14.9%, England 17.9%

    Ethnicity

    White78.3%
    Asian14.7%
    Black3.3%
    Mixed2.3%
    Other1.4%

    Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Bolton LA)1,9232,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.0%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)58.9%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Bolton LA)9581,0219552024/25
    Falls deaths, all ages, per 100,000 (Bolton LA)19.018.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation reaches 52.2% of patients, spanning a 56.7 pp inter-practice range

    In Breightmet & Little Lever PCN, 52.2% of registered patients live in Core20 areas, exceeding Bolton (47.8%), NHS Greater Manchester Integrated Care Board (40.7%) and England (21.0%). While weighted practice rates average 51.8% (a 0.41 pp reconciliation difference), practice concentration spans 56.7 pp, from 14.3% at Little Lever Health Centre 2 to 71.0% at The Alastair Ross Medical Practice. Caseload volume highlights delivery demands: The Dunstan Partnership carries 6,182 estimated Core20 patients (61.8%), The Alastair Ross Medical Practice 5,378 (71.0%), and Tonge Fold Health Centre 4,501 (64.5%).

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Alastair Ross71.0% · 5,378 patients
    Tonge Fold64.5% · 4,501 patients
    Dunstan61.8% · 6,182 patients
    Little Lever 141.8% · 1,990 patients
    Spring View18.1% · 965 patients
    Little Lever 214.3% · 407 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    444

    SMI register

    1.19% recorded prevalence

    254

    Learning disability register

    0.68% recorded prevalence

    13

    Care homes, 446 beds

    In the PCN catchment

    9.8%

    Provide unpaid care

    Bolton (LAD), Census 2021

    The PCN records 444 patients on the severe mental illness register (1.2% prevalence) and 254 on the learning disability register (0.7%), both above England (1.0% and 0.6%). The catchment also includes 13 care homes with 446 beds, although bed counts do not establish registered patient occupancy. With both registers above England benchmarks, maintaining routine physical-health checks and care-home coordination may represent key inclusion-health workloads to protect.

    Severe mental illness: physical health checks

    Recorded SMI blood pressure checks reach 84.4% and BMI checks 83.2%, above England (83.4% and 82.1%). However, three-year BMI checks fell 0.7 pp against England's +5.1 pp rise, which may indicate physical monitoring slippage.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    6,198

    Hypertension register

    +5.08%

    Register growth, 3 yrs

    Bolton (LAD) +4.70% · England +5.60%

    −4.80pp

    BP control, under 80

    ≤140/90 · −3.44pp aged 80+

    +724

    More patients by 2030

    Forecast 6,922 (18.32%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 16.6% (6,198 patients), above Bolton (14.8%), the ICB (14.4%) and England (15.2%). While 90.1% of patients had a recent blood pressure check (England 90.0%), control to target is 69.2%, having fallen 6.0 pp over three years (England +2.5 pp). For patients under 80, control is 66.1% (Bolton 67.3%, the ICB 68.6%, England 67.8%), having fallen 4.8 pp (England +2.1 pp). Falling blood pressure control despite high check coverage may reflect recall or titration slippage for patients under 80.

    Lipids and statins

    For patients with QRISK ≥ 20%, lipid-lowering therapy coverage is 69.8%, exceeding Bolton (63.0%), the ICB (67.0%) and England (63.6%). Diabetic statin coverage also leads England, reaching 76.6% without CVD and 86.5% with CVD. Higher lipid therapy coverage than England indicates strong primary prevention reach, supporting ongoing routine review schedules.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202667,796£2.00£1.94£1.86£135,592
    Cardiovascular (all), 202591,791£4.16£3.15£3.33£381,851

    In 2026, lipid-modifying drugs cost £2.00 per item across 67,796 items, above Bolton (£1.81), the ICB (£1.94) and England (£1.86), spending £9,491 more than at England's unit cost. Unit-cost differences represent a descriptive cost indicator rather than an efficiency measure, though formulary review could identify local spend drivers.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −9.21%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +0.39%

    Asthma prevalence, PCN 3-yr % change

    Recorded COPD prevalence is 3.2% (1,192 patients) and asthma prevalence is 7.4% (2,595 patients), both above England (1.9% and 6.6%). Annual reviews also exceed national levels at 81.5% for COPD (England 76.4%) and 70.2% for asthma (England 65.7%). However, both show three-year erosion: COPD reviews fell 7.4% (England +2.8%) and asthma reviews fell 9.2% (England +4.4%), leaving about 770 asthma patients unreviewed. Alongside elevated youth asthma prescribing (2,437 items per 1,000 aged 5-19 vs 1,488 in England), practices should prioritise proactive respiratory recall.

    Cancer register and children's immunisation

    Cancer prevalence is 3.9% (1,449 patients), in line with England (3.8%). In childhood immunisations, age-5 MMR dose 1 coverage reaches 99.1% (England 91.7%), but dose 2 drops to 91.5% (a 7.6 pp difference) and the 4-in-1 booster reaches 88.7%, both below the 95.0% target. Slower uptake of second doses and boosters leaves a vulnerable cohort before school entry, making pre-school recall the key operational opportunity.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months93.3%

    England 91.0%

    6-in-1 complete primary course at 24 months93.4%

    England 92.2%

    MMR dose 1 at 24 months93.4%

    England 88.3%

    MMR dose 2 at age 591.5%

    England 82.8%

    4-in-1 pre-school booster at age 588.7%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, 55.6% of cancers with a known stage across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 staged cases), in line with England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. Staging was known for 70.8% of registrations (11,679 of 16,492). Closing the ICB ambition gap requires about 2,270 additional early-stage diagnoses annually. Early staging rose 3.1 pp from 52.4% in 2013. These ICB figures reflect wider system staging rather than PCN performance, while PCN cervical screening (68.6%) and breast screening (72.5%) both exceed England.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), Bolton NHS Foundation Trust achieved 69.7% on the cancer 62-day referral to treatment standard, 15.3 pp below the 85.0% standard. This trailed Northern Care Alliance NHS Foundation Trust (78.6%), Manchester University NHS Foundation Trust (72.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). However, Bolton met the 28-day faster diagnosis standard at 80.5% (standard 75.0%) and the 31-day combined treatment standard at 96.5% (standard 96.0%). For diagnostics in Jul 2026, 25.3% waited 6+ weeks for cystoscopy at Bolton (England 24.4%), while 6+ week MRI waits were 2.0% (England 21.4%).

    Pathways within standard (%)BoltonNorthern Care AllianceManchesterGreater Manchester ICBEngland
    28-day faster diagnosis (75%)80.4875.2080.0679.5379.32
    31-day treatment (96%)96.5094.5492.5496.4992.50
    62-day referral to treatment (85%)69.6678.6572.8575.7371.16
    Diagnostic waits over 6 weeks (%)BoltonNorthern Care AllianceManchesterEngland
    MRI2.055.0911.6821.40
    CT19.404.1014.669.92
    Echocardiography3.4831.484.9128.48
    Colonoscopy1.3340.044.5130.83
    Gastroscopy2.0636.4829.3529.02
    All 15 DM01 tests15.7815.718.9823.14
    Community services activityBolton residentsGreater Manchester ICB
    Care contacts49,315573,310
    Referrals4,07594,470
    Patients with a contact17,765183,535

    Community services (residents of Bolton), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 51.6% of community service contacts among Bolton borough residents (25,460 of 49,315 total contacts). This highlights that community services predominantly manage older-age care across the local authority, although activity is published at borough resident level rather than by primary care network.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Patient phone access varies by 48.5 percentage points across practices

    Across 2025/26, QOF overall achievement ranged from 85.7% at Little Lever Health Centre 1 to 96.8% at Spring View Medical Centre (England 92.5%). Vaccination and immunisation achievement spanned 46.7 pp, trailing England (55.2%) down to 24.8% at The Alastair Ross Medical Practice.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Tonge Fold9764.583.3%84.5%88.5%
    Little Lever 19641.859.6%75.7%84.7%
    Dunstan11661.851.6%77.8%82.9%
    Spring View10218.154.4%65.6%78.4%
    Little Lever 210214.375.1%77.6%73.6%
    Alastair Ross8471.034.8%75.7%67.0%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNBolton (LAD)AssetPCNBolton (LAD)
    Care homes (catchment)13 (446 beds)n/aSchools (catchment)50n/a
    Children's centres418Places of worship31144
    Libraries17Primary schools (LA maintained)961
    Primary academies1132Special schools13

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Respiratory and heart failure recall audit

    Asthma reviews (70.2%, 2,595 register) fell 9.2% over 2023 to 2025 (England +4.4%), leaving 772 (about 770) unreviewed; COPD reviews fell 7.4% and heart failure 9.5%. For discussion: run a shared annual review recall across the 2,595 asthma, 1,192 COPD and 331 heart failure registers, starting in Core20 practices. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension titration and under-80 recall

    Across 6,198 hypertension patients (16.6%), target control is 69.2% (England 70.3%), falling 8.0% or 6.0 pp (England +3.6%, +2.5 pp); under-80 control (66.1%) fell 4.8 pp. For discussion: deploy clinical pharmacists to review and titrate patients on the 6,198 hypertension register above target, focusing on patients under 80. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school booster and phone access review

    Age-5 MMR drops 7.6 pp from dose 1 (99.1%) to dose 2 (91.5%), with 4-in-1 at 88.7% (below 95.0% by 6.3 pp); phone access spans 48.5 pp (34.8% to 83.3%). Low cost, quick to run.

    Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.

    Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Differentiated Core20 resource allocation (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check audit (p4)Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Blood pressure titration audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026Practice
    Telephone access and triage review (p9)GPPS good overall experience of the practice10YHP, hospital to communityPractice
    Option 1 · Respiratory and heart failure recall audit (p12)Asthma register · COPD register · Heart failure registerCore20PLUS5 respiratoryPCN
    Option 2 · Hypertension titration and under-80 recall (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Pre-school booster and phone access review (p12)Core20 cohort (IMD quintile 1) · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5Core20PLUS5 · 10YHP equity test · 10YHP sickness to prevention · 95% targetPCN & Practice
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15